Hims & Hers stopped offering a compounded version of Novo Nordisk’s Wegovy after escalating legal pressure from federal regulators and calls for criminal review. The company said it “decided to stop offering access” following warnings from the FDA and renewed scrutiny over unauthorized compounding of approved GLP‑1 products. Regulators including the Department of Justice have been urged to investigate firms selling unapproved, compounded versions of branded GLP‑1 drugs; the developments mark a sharp enforcement turn as demand for obesity medicines surges. Industry lawyers and brand manufacturers have argued that mass compounding of approved therapies undermines drug safety and intellectual‑property protections. For companies in telehealth and compounding, the episode signals heightened regulatory risk and potential legal exposure when repackaging or compounding high‑demand branded agents. Biotech and pharma firms that supply proprietary GLP‑1 molecules face parallel commercial and legal pressures as new entrants test the boundaries of compounding and secondary manufacturing.